Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Food and Drug Administration Approval Letter for Alemtuzumab
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.
Ustekinumab.
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation.
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
BTG Commences Phase IIa Study of Multiple Sclerosis
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse.
Teaching NeuroImages: MRI in advanced neuromyelitis optica.
Natalizumab Use During the Third Trimester of Pregnancy.
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis.
Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.

Pages